Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/3/2024 | $142.00 | Buy | Jefferies |
4/8/2024 | $117.00 | Buy | Craig Hallum |
2/20/2024 | $68.00 → $85.00 | Strong Buy → Outperform | Raymond James |
12/29/2023 | $75.00 → $85.00 | Buy | BTIG Research |
12/14/2023 | $70.00 | Buy | Guggenheim |
12/13/2023 | $70.00 | Outperform | Wolfe Research |
11/13/2023 | $68.00 | Outperform → Strong Buy | Raymond James |
9/28/2023 | $48.00 | Mkt Perform | Bernstein |
Test demonstrated high performance metrics in largest study of its kind in the US with sensitivity of 100% and specificity of 99.3% Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that Obstetrics & Gynecology (also known as The Green Journal) published the Company's clinical validation study on its cell-free DNA (cfDNA) Fetal RhD noninvasive prenatal test (Fetal RhD NIPT). Natera's study is the largest clinical validation of a fetal RhD test performed in the United States to date, with fetal RhD status confirmed via newborn serology in 655 RhD-negative pregnant patients. The study provides compelling scientific evidence on the ability of
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Prospera Lung test has met coverage requirements from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services (MolDX) Program for single lung transplant (SLT) recipients. This coverage applies to SLT patients in the surveillance setting. SLT patients make up ~20% of all U.S. lung transplants1. These patients are at an increased risk for acute rejection and also for complications from invasive procedures like biopsies due to common factors including advanced age, frailty, comorbidities, and functional dependency on a single lung. This creates an increased ne
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present new SignateraTM data at the San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 10-13 in San Antonio, TX. Natera and its collaborators will present a total of six abstracts. "We are proud to share this new data on Signatera at SABCS that underscores our commitment to generating evidence on the clinical utility of Signatera for patients with breast cancer," said Angel Rodriguez, M.D., senior medical director at Natera. The full list of abstracts with selected highlights are as follows: ZEST Clinical Trial Oral Presentation #GS3-01 | Dec. 13 | Presenter: Nich
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee
Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations
AUSTIN, Texas, May 24, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg
Jefferies resumed coverage of Natera with a rating of Buy and set a new price target of $142.00
Craig Hallum resumed coverage of Natera with a rating of Buy and set a new price target of $117.00
Raymond James downgraded Natera from Strong Buy to Outperform and set a new price target of $85.00 from $68.00 previously
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product revenues grew 64.4% over the same period. Generated a gross margin of 61.8% in the third quarter of 2024, compared to a gross margin of 45.1% in the third quarter of 2023. Processed approximately 775,800 tests in the third quarter of 2024, compared to approximately 626,000 tests in the third quarter of 2023, an
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 2024, after the market closes on Nov. 12, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's Third Quarter 2024 Financial Results Date: Tuesday, Nov. 12, 2024 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID: 7684785 Webc
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $413.4 million in the second quarter of 2024, compared to $261.4 million in the second quarter of 2023, an increase of 58.1%. Product revenues grew 59.3% over the same period. Generated a gross margin of 58.8% in the second quarter of 2024, compared to a gross margin of 45.2% in the second quarter of 2023. Processed approximately 760,300 tests in the second quarter of 2024, compared to approximately 617,200 tests in the second quarter of 2023, an incr
Natera's (NYSE:NTRA) short percent of float has risen 15.19% since its last report. The company recently reported that it has 6.38 million shares sold short, which is 5.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.14 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is imp
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 18.07% on an annualized basis producing an average annual return of 31.07%. Currently, Natera has a market capitalization of $12.47 billion. Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $386.36 today based on a price of $101.57 for NTRA at the time of writing. Natera's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 19.94% on an annualized basis producing an average annual return of 33.11%. Currently, Natera has a market capitalization of $13.71 billion. Buying $1000 In NTRA: If an investor had bought $1000 of NTRA stock 5 years ago, it would be worth $4,293.85 today based on a price of $111.64 for NTRA at the time of writing. Natera's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewe
144 - Natera, Inc. (0001604821) (Subject)
10-Q - Natera, Inc. (0001604821) (Filer)
8-K - Natera, Inc. (0001604821) (Filer)